Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTQAJF1)

Molecule-Related Drug & Molecule List

Molecule-Related Drug List

Molecule Type:

DTT

DTP

DME

Drug Status:

Discontinued Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-10311795	DM7OTQS	Chronic obstructive pulmonary disease	CA22	Phase 2	[1]
------------------------------------------------------------------------------------

9 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Peptide analog 55	DMVLP8H	N. A.	N. A.	Patented	[2]
Peptide analog 56	DMBCFJU	N. A.	N. A.	Patented	[2]
Peptide analog 57	DM6IQWE	N. A.	N. A.	Patented	[2]
Peptide analog 58	DM7X62M	N. A.	N. A.	Patented	[2]
Peptide analog 59	DMZAMNX	N. A.	N. A.	Patented	[2]
Peptide analog 60	DMMSTNA	N. A.	N. A.	Patented	[2]
Peptide analog 61	DM45JMT	N. A.	N. A.	Patented	[2]
Peptide analog 62	DM28NK0	N. A.	N. A.	Patented	[2]
Peptide analog 70	DMN43Q5	N. A.	N. A.	Patented	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Patented Agent(s)

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aloxistatin	DMGW07M	Neurological disorder	6B60	Discontinued in Phase 3	[3]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[4]
------------------------------------------------------------------------------------

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,3-Dibenzyl-[1,3]diazetidine-2,4-dione	DM8NARQ	Discovery agent	N.A.	Investigative	[5]
Bis-Napthyl Beta-Ketophosphonic Acid	DM0K6QH	Discovery agent	N.A.	Investigative	[6]
PMID22595175C4g	DM9SLUK	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecule Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
2	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
3	Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46.
4	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
5	Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4.
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7	N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7.